98%
921
2 minutes
20
Background: It remains unclear whether ursodeoxycholic acid (UDCA) treatment improves long-term outcomes in patients with primary sclerosing cholangitis (PSC). In this study, we investigated whether UDCA treatment is associated with improved liver transplantation (LT)-free survival in a cohort of Japanese patients with PSC.Journal instruction requires a city and country for affiliations; however, these are missing in affiliation [6]. Please verify if the provided city and country are correct and amend if necessary.'Tokyo, Japan' is correct.
Methods: We used retrospective data from the Japanese PSC registry that included 435 patients with PSC. In this study, we enrolled patients with a complete dataset at diagnosis, along with the diagnosis year, treatment protocol, follow-up period, and outcome data. The association between UDCA treatment and all-cause death or LT was analyzed using Cox regression and inverse probability of UDCA treatment weighting (IPTW)-adjusted Cox regression models adjusted for covariates.
Results: Among 435 patients with PSC, 110 were excluded due to insufficient or missing data, and the remaining 325 patients (male, 187 (58%); mean age at diagnosis, 45.8 years) were enrolled. The mean follow-up period was 5.1 years, and 57 deaths and 24 LTs occurred during observation. UDCA was administered to 278 patients (86%). The Cox regression model demonstrated that UDCA treatment was associated with an improvement in LT-free survival [adjusted hazard ratio (aHR) 0.47, 95% confidence interval (CI) 0.28-0.78, p = 0.003]. In addition, the IPTW-adjusted model indicated a significant association between UDCA and LT-free survival (aHR 0.43, 95% CI 0.25-0.75, p = 0.020). Sensitivity analysis excluding patients treated with bezafibrate indicated a similarly significant association between UDCA treatment and LT-free survival.
Conclusion: In this Japanese PSC cohort, UDCA treatment was significantly associated with improved LT-free survival.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00535-022-01914-3 | DOI Listing |
Clin Ther
September 2025
F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Center for Pharmacoepidemiology Research and Training, University of Pennsylvania Perelman School of Medicine, Philade
Purpose: Cholelithiasis is associated with decreased risk of age-related macular degeneration (AMD). Ursodeoxycholic acid (UDCA), a bile acid used to dissolve cholesterol gallstones, has been shown to be retina-protective in several mouse models. This study sought to determine if UDCA may protect against AMD.
View Article and Find Full Text PDFInt J Biol Macromol
September 2025
College of pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China; Shandong Key Laboratory of Digital Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China. Electronic address:
Hepatocellular carcinoma (HCC) poses a serious threat to human life and health. Nowadays, liver-targeting drug delivery systems have been proven as a promising strategy in treating HCC. Angelica sinensis polysaccharide (ASP), a plant polysaccharide with good biocompatibility, has excellent aqueous solubility and intrinsic liver-targeted capability.
View Article and Find Full Text PDFCurr Pharm Des
August 2025
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Guwahati, Sila Katamur (Halugurisuk), Changsari, Kamrup, Assam, 781101, India.
Cholelithiasis, particularly cholesterol-bearing-stones, is one of the gastrointestinal diseases representing a substantial global health burden. The five key primary factors inducing cholesterol-bearing-stones include genetics, hepatic cholesterol hypersecretion, rapid phase transition of cholesterol, gallbladder hypomotility, and specific intestinal factors. To date, laparoscopic cholecystectomy remains the primary treatment approach for cholelithiasis patients.
View Article and Find Full Text PDFInn Med (Heidelb)
September 2025
Bereich Hepatologie, Medizinische Klinik II, Universitätsklinikum Leipzig, Leipzig, Deutschland.
Primary biliary cholangitis (PBC) is a chronic inflammatory, autoimmune-mediated liver disease that progresses to fibrosis and cirrhosis if left untreated. In addition to preventing complications, the management of burdensome symptoms, particularly pruritus, represents a key therapeutic goal. Ursodeoxycholic acid (UDCA) is the established first-line treatment; however, up to 40% of patients show an inadequate response and require second-line treatment.
View Article and Find Full Text PDFJ Chromatogr B Analyt Technol Biomed Life Sci
September 2025
Guigang People's Hospital, Nanning, China. Electronic address:
Non-alcoholic steatohepatitis (NASH), a globally prevalent metabolic disorder, exhibits a complex and incompletely understood pathogenesis with limited clinical treatment options available. Studies have shown that Quyu Huazhuo Decoction (QYHZD) can effectively reduce insulin resistance and improve liver function in NASH patients, though its underlying mechanisms remain unclear. Using a high-fat diet (HFD)-induced NASH rat model, the present study employed 16S rDNA sequencing along with targeted metabolomics of bile acids (BAs) and short-chain fatty acids (SCFAs) to systematically evaluate the therapeutic effects of QYHZD.
View Article and Find Full Text PDF